TransMedics Group, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
TMDX$90.95-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Accumulated | |||||
|---|---|---|---|---|---|
| Other · Total | |||||
| Common Stock · Comprehen- · Accumulated · Stockholders’ | |||||
| Shares | Amount | sive Income | Deficit | Equity | |
| Balances at December 31, 2025 | 34,267,802 | $750,926 | $124 | $(277,950) | $473,100 |
| Issuance of common stock upon the exercise of common stock options | 59,661 | 2,212 | — | — | 2,212 |
| Issuance of common stock in connection with employee stock purchase plan | 16,321 | 1,688 | — | — | 1,688 |
| Net issuance of common stock upon vesting of restricted stock units | 201,937 | (138) | — | — | (138) |
| Stock-based compensation expense | — | 9,952 | — | — | 9,952 |
| Foreign currency translation adjustment | — | — | (122) | — | (122) |
| Net income | — | — | — | 7,315 | 7,315 |
| Balances at March 31, 2026 | 34,545,721 | $764,640 | $2 | $(270,635) | $494,007 |
| Accumulated | |||||
|---|---|---|---|---|---|
| Other · Total | |||||
| Common Stock · Comprehen- · Accumulated · Stockholders’ | |||||
| Shares | Amount | sive Loss | Deficit | Equity | |
| Balances at December 31, 2024 | 33,617,972 | $697,208 | $(364) | $(468,241) | $228,603 |
| Issuance of common stock upon the exercise of common stock options | 77,101 | 1,742 | — | — | 1,742 |
| Issuance of common stock in connection with employee stock purchase plan | 24,268 | 1,286 | — | — | 1,286 |
| Restricted common stock forfeitures | (2,880) | — | — | — | — |
| Vesting of restricted stock units | 111,419 | — | — | — | — |
| Stock-based compensation expense | — | 8,958 | — | — | 8,958 |
| Foreign currency translation adjustment | — | — | 37 | — | 37 |
| Net income | — | — | — | 25,682 | 25,682 |
| Balances at March 31, 2025 | 33,827,880 | $709,194 | $(327) | $(442,559) | $266,308 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.